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PURPOSE. To determine the effect of 15 individual ABCA4 mutations on disease severity.
METHODS. Eighty-two patients harboring 15 distinct ABCA4 mutations in trans with null
(hemizygous), 10 homozygous, and 20 nullizygous patients were recruited. Age of onset was
determined from medical histories. Electroretinography (ERG) responses were classified into
three groups (normal; cone dysfunction; cone and rod dysfunction). The dark-adapted bright-
flash (DA 10.0) a-wave amplitudes and the light-adapted flicker ERG (LA 3.0 30 Hz)
amplitudes were plotted against age and compared with the nullizygous patients. Fundus
autofluorescence imaging (FAF) was assessed when available.
RESULTS. Patients hemizygous for p.G1961E and p.R2030Q had normal ERGs. Patients
harboring p.R24H, p.R212C, p.G863A/delG, p.R1108C, p.P1380L, p.L2027F, and
c.5714þ5G>A had abnormal ERGs (ERG group 2 or 3) at older ages, in most cases with
significantly higher amplitudes than nullizygous patients. Mutations p.L541PþA1038V,
p.E1022K, p.C1490Y, p.E1087K, p.T1526M, and p.C2150Y were associated with abnormal
ERGs (group 2 or 3) and amplitudes comparable to those of nullizygous patients. The majority
of patients, including those harboring p.G1961E, had foveal atrophy; while both patients
harboring p.R2030Q had foveal sparing. Most patients harboring intermediate and null-like
mutations displayed FAF abnormalities extending beyond the vascular arcades.
CONCLUSIONS. In the hemizygous state, 2/15 ABCA4 alleles retain preserved peripheral retinal
function; 7/15 are associated with either preserved or only mildly abnormal retinal function,
worse in older patients; 6/15 behave like null mutations. These data help characterize the
degree of dysfunction conferred by specific mutant ABCA4 proteins in the human retina.
Keywords: ABCA4, retinal dystrophy, electrophysiology, inherited retinal disease, fundus
autofluorescence
Biallelic mutation of the ABCA4 gene is the most commoncause of inherited retinal disease, leading to significant
permanent blindness in many affected people.1–4 In the era of
emerging therapies for genetically determined disease, it is
critical in the design and interpretation of intervention trials to
understand the natural history and the causes of disease
variability. Several in vitro and animal studies investigating the
effects of various ABCA4 mutations have been performed,5–12
but clinical phenotypic correlations have not yet been
established for most. Retinal disease caused by ABCA4
mutations includes phenotypes such as early-onset cone–rod
dystrophy, limited macular dystrophy, and late-onset foveal
sparing disease. Attempts at establishing genotype–phenotype
correlations in humans have been hindered by age-related
differences in phenotype, vast allelic heterogeneity, and the fact
that the combined effects of two alleles, not one, determine the
clinical presentation in affected people.13–15 This study partly
surmounts the complexity by studying those with a genotype in
which one of the two alleles is an established ‘‘null’’ allele,
allowing the clinical effect of the remaining allele to be
determined unambiguously. We use a robust objective measure
of the peripheral retinal function, the electroretinogram (ERG),
and fundus autofluorescence (FAF) imaging of the macula to
study the effect of 15 different ABCA4 alleles.
METHODS
Patient Selection
The data derive from 82 patients (46% male, median age 31
years; range 9–75) harboring one of 15 different ABCA4
mutations (Table 1) in trans with a null mutation (referred to
as hemizygous for the purpose of this paper). A further cohort
of 20 patients, harboring two null mutations in trans
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(nullizygous), were examined in parallel (60% male, median
age 12 years; range, 6–40) and used for comparison, and one
nullizygous patient without ERG data was recruited for FAF
comparison in his age group. All patients were recruited from a
cohort of 488 genetically confirmed patients with ABCA4-
retinopathy. Mutations were included if there was at least one
hemizygous patient with ERG data. If the phenotype was mild
at a young age (normal ERG at age < 20 years), there had to be
at least one older patient with the same mutation (>40 years)
in an attempt to assess possible ERG deterioration with age. In
addition, for mutations associated with severe phenotypes, a
cohort of homozygous patients (n¼ 10) was reviewed in order
to examine the clinical effect of doubled allele dosage. That is,
the clinical consequence of a missense allele behaving like a
null would be comparable in the hemi- and homozygous states,
whereas one with residual function might be expected to show
an improved clinical outcome when homozygous, where gene
dosage is twice that of a hemizygote. For the purpose of this
study, mutation was considered to be null if it was either a stop
mutation, a frame-shifting mutation resulting in a stop codon,
predicted to undergo nonsense-mediated decay,16 or a splicing
mutation previously shown to behave as null, that is, c.5461-
10T>C17 or c.6729þ4del15.18 Other splice-site mutations,
including those in the canonical regions, were excluded to
minimize the potential effects of leaky splicing.19 The
genotypic data appear in Supplementary Table S1. The 15
mutations studied here accounted for 36% (349) and the null
mutations for 27% (261) of the 976 disease-associated alleles of
the total patient cohort.
Clinical Assessment
Disease onset was defined as the age when patients first
noticed visual problems. Electroretinography (ERG) incorpo-
rated the recommendations of the International Society for
Clinical Electrophysiology of Vision (ISCEV).22 The pattern
ERG, reflecting macular function, was indistinguishable from
noise in the majority of patients (data not shown). These data
were not, therefore considered in this study. Full-field ERG
responses were detectable in most, and were used to study the
degree of peripheral retinal dysfunction. Patients were
classified by experienced electrophysiologists (GEH, AGR) into
one of three ERG groups23: normal (group 1; dysfunction
confined to the macula), generalized cone system dysfunction
(group 2), or cone and rod system dysfunction (group 3). Age
at ERG examination, age at onset, ERG group, and genotype for
each patient are shown in Supplementary Table S1. The data
showed a high degree of interocular symmetry, and right eye
data were used for analysis. Fundus autofluorescence and
optical coherence tomography (OCT; Spectralis, Heidelberg,
Germany) were assessed when available (76/82 patients).
Categorizing ABCA4 Mutations
The clinical impact of the different ABCA4 mutations was
determined using ERGs in the following steps. (1) The
proportion of patients with group 1 ERG was determined for
each genotype, and on the basis of that, the categories of mild,
intermediate, and null-like mutations were established. (2) In
order to confirm that the categories had clearly separate
amplitude progression patterns and to further subclassify the
intermediate category, the DA 10.0 (dark adapted; ERG to flash
strength of 10.0 cd.s.m2) a-wave amplitudes were plotted
against age and compared with a regression line fitting
equivalent measurements in nullizygous patients (where the
line’s 95% confidence interval was used to detect a significant
difference). The LA 3.0 30-Hz (light-adapted ERG, flash
strength 3.0 cd.s.m2 presented at 30 Hz) amplitude was
analyzed in a similar manner; other ISCEV Standard ERG
parameters were analyzed as a supportive measure. (3)
Homozygous patients were assessed for mutations associated
with the most severe phenotypes to determine whether the
addition of a further identical allele resulted in a milder
phenotype. The relationship between amplitude and peak time
of DA 10.0 a-wave and LA 3.0 30 Hz was explored in patients
with abnormal ERGs, to determine whether any of the
mutations produced a different mode of disease progression
(e.g., peak time change prior to amplitude loss or vice versa).
TABLE 1. Number of Included Patients for Each of the Studied ABCA4 Mutations
Mutation n
Base Change Amino Acid Change Hemizygous Homozygous
c.5882G>A p.G1961E 23 NA
c.2588G>C p.G863A/delG* 19 NA
c.1906C>T p.L2027F 9 NA
c.6449G>A p.C2150Y 6 NA
c.5714þ5G>A† Splice-site mutation 5 NA
c.71G>A p.R24H 3 NA
c.6089G>A p.R2030Q 2 NA
c.634C>T p.R212C 3 2‡
c.4577C>T p.T1526M 3 2
c.3322C>T p.R1108C 2 1
c.3064G>A p.E1022K 1 2
c.4139C>T p.P1380L 2 1
c.4469G>A p.C1490Y 2 1
c.3259G>A p.E1087K 1 1
c.1622T>Cþc.3113C>T complex allele p.L541Pþp.A1038V complex allele 1 /
Total 82 10
Nullizygous 20, plus 1 without ERG data
* c.2588G>C is associated with two different protein products in approximately equal ratios, glycine-to-alanine substitution at codon 863
(p.G863A) and removal of codon 863 due to an activation of a cryptic splice acceptor site in exon 17 (p.G863del),13 and is, for the purpose of this
study, referred to as p.G863A.
† c.5714þ5G>A has been shown to result in a mixture of normally and abnormally spliced ABCA4 protein.20
‡ The patients were included in a previous paper.21
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The ERG data from 137 healthy controls (n ¼ 137)24,25 were
plotted on all charts as reference for the normal age-related
change in ERG amplitudes.
Genetic Analysis
The majority of genotypes were ascertained by next-generation
sequencing as a part of retinal panel at Casey Eye Institute.
Specifically, direct testing for mutations in the genes of the
Stargardt/Macular dystrophy SmartPanel v4 (613 primer sets)
was performed by PCR amplification and next-generation
sequencing. Polymerase chain reaction primer sets were
printed onto a specific chip. Each primer set is duplicated on
the chips in order to avoid random PCR failure. Any low-
coverage region (<1003) was covered afterward by PCR and
Sanger sequencing. Identified mutations and novel variations
were confirmed by Sanger sequencing. All exons and exon/
intron boundaries were sequenced. Exon 1 is defined as the
exon having the start codon ATG. Codon 1 corresponds to the
start ATG and nucleotide 1 to the A. The canonical ABCA4
transcript sequence, ENST00000370225, was used to compare
exonic sequence. Phase of the two variants was explored in
the majority of patients (when the relatives were available),
and in each case they were in trans. When segregation was not
possible, the variants were assumed to be in trans if (1)
phenotype was consistent with ABCA4-retinopathy; (2) the
patient had exactly two ABCA4mutations (with complex allele
p.L541Pþp.A1038V counting as one); and (3) the two ABCA4
mutations were not previously reported in cis in a complex
allele. All included patients met those criteria.
Statistical Analysis
Statistical analysis was performed using SPSS software v. 22
(IBM SPSS Statistics, IBM Corporation, Chicago, IL, USA). The
Mann-Whitney U test was used to test for significant
differences in median age of onset between the patients,
hemizygous for each of the studied mutations, and the
nullizygous group. The 95% confidence interval of the
nullizygous regression line was used to determine whether
the ERG amplitudes of the hemizygous patients differed
significantly from those of the nullizygous patients. Fisher’s
exact test was used to compare the frequencies of an abnormal
ERG among different genotypes associated with widespread
FAF abnormalities.
Institutional Review Board (IRB)/Ethics Committee approv-
al was obtained. The research adhered to the tenets of the
Declaration of Helsinki.
RESULTS
Age of Disease Onset
Six mutations (c.5714þ5G>A, p.R24H, p.G863A, p.G1961E,
p.L2027F, and p.R2030Q) had significantly later median ages of
onset (Mann-Whitney U test, P < 0.05) compared to the
nullizygous group, while seven mutations (p.R212C,
p.L541PþA1038V, p.E1022K, p.R1108C, p.P1380L, p.C1490Y,
and p.C2150Y) were comparable to the nullizygous group (Fig.
1A); onset data were not available for p.E1087K and p.T1526M.
Electroretinography
A summary of the main ERG parameters for each of the studied
mutations appears in Supplementary Table S2. Figure 1B shows
the frequency of different ERG groups for each of the studied
mutations. Two mutations were consistently associated with
normal (group 1) ERGs, and six mutations were consistently
associated with abnormal ERGs (group 2 or 3). Seven
mutations could be associated with either normal or abnormal
ERGs. The age distribution analysis of the latter revealed a
tendency toward a normal ERG at younger ages and abnormal
ERG at older ages (Fig. 1C), but the number of patients was too
low for statistical analysis. None of the mutations was
exclusively associated with ERG group 2. Patients with ERG
group 2 were further explored in terms of age and disease
duration (Supplementary Fig. S1). Within each genotype, the
age and/or disease duration of those patients fell between
FIGURE 1. (A) Box plot chart showing the distribution of ages of onset
of visual symptoms for different genotypes. Mutations (all in trans with
null) are marked below each box plot. Significantly delayed onset in
comparison to the nullizygous group is marked by asterisks (Mann-
Whitney U test, P < 0.05). Dashed line represents the latest age of
onset observed in the nullizygous group. (B) Frequency of different
ERG groups for each mutation. The median ages of patients for each of
the studied mutations are noted below the columns. (C) Box plot chart
showing the age distribution of patients harboring the intermediate
mutations, separately for patients with normal (ERG group 1) and
abnormal (ERG group 2 or 3) ERG. For each mutation the median age of
patients with normal ERG was lower than the median age of patients
with abnormal ERG. Circular symbols represent single cases.
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those in ERG groups 1 and 3, but the low number of patients
precluded statistical analysis.
The plots of DA 10.0 a-wave amplitudes against age show
that patients hemizygous for p.G1961E or p.R2030Q had
significantly better amplitudes than nullizygous patients in all
cases (Fig. 2A) and were thus classified as mild. In contrast,
none of the patients hemizygous for p.E1022K, p.E1087K,
p.C1490Y, p.T1526M, p.C2150Y, or p.L541PþA1038V had
significantly better amplitudes than nullizygous patients (Fig.
2D), and were thus classified as null-like. The majority of
patients hemizygous for c.5714þ5G>A, p.R24H, p.G863A, or
p.L2027F had significantly better amplitudes than nullizygous
patients, even in cases where the ERG amplitudes were
subnormal (mostly older patients) (Fig. 2B). Patients hemizy-
gous for R212C, p.R1108C, or p.P1380L had significantly better
amplitudes at younger (<20 years) but not older ages (>40
years; Fig. 2C). The latter two groups are thus classified as
intermediateþ and intermediate.
Analysis of other ERG parameters was largely consistent with
these findings (Fig. 3; Supplementary Fig. S2; Supplementary
Table S2). None of the mutations was notably different from the
others in terms of the relationship between amplitude loss and
peak time delay (Supplementary Fig. S4). Analysis of ERG
amplitudes against disease duration was also performed, with
consistent results; age was chosen as the main parameter for
classificationbecauseof a larger set of available data and the ability
to consider age-related normative data (Supplementary Fig S3).
Mutations resulting in severe ERG phenotypes were
assessed in homozygous states, when available (Fig. 4). Patients
homozygous for p.R212C, p.R1108C, and p.P1380L had
significantly better amplitudes in comparison to the equivalent
hemizygous patients (Fig. 4A), whereas patients homozygous
for E1022K, p.E1087K, p.C1490Y, and p.T1526M were still
similar to nulls (Fig. 4C). The analysis of the LA 3.0 30-Hz
amplitudes was consistent with these findings with the
exception of p.T1526M (Supplementary Fig. S2).
Fundus Autofluorescence and Optical Coherence
Tomography
The structural changes in the macula were assessed using FAF
and OCT for each severity class after classifying the mutations
by ERGs (Supplementary Table S3; Fig. 5). Two distinct
phenotypes were observed for the mild mutations p.G1961E
and p.R2030Q. The majority of p.G1961E patients had a
notable loss of photoreceptors in the fovea, and flecks were
either absent or localized within the vascular arcades, while
both p.R2030Q patients had foveal sparing and widespread
flecks and mottling in the macula and extending beyond the
vascular arcades (representative OCT images shown in Fig. 5).
Intermediate mutations displayed a relatively homogenous
phenotype for all genotypes, with the fundus abnormalities
extending beyond the vascular arcades in 85% (34/40) of cases.
In the early stages, patients often exhibited a relatively small
FIGURE 2. The DA 10.0 (dark adapted; ERG to flash strength of 10.0
cd.s.m2) a-wave amplitudes of patients hemizygous for 15 different
ABCA4 mutations, plotted by age. Mutations of similar severity are
divided into four groups and shown separately. The gray area
represents the 95% confidence interval of the healthy volunteers. On
each chart the nullizygous patients are shown as a baseline reference
with their regression line and its confidence intervals. (A) Mutations
consistently associated with normal ERG (ERG group 1). (B) Mutations
resulting in abnormal ERG at older ages, with amplitudes significantly
better than those of the nullizygous patients in most cases. (C)
Mutations resulting in abnormal ERG at older ages, with amplitudes
comparable with those of the nullizygous patients. (D) Mutations
consistently associated with abnormal ERG (ERG group 3) with
amplitudes comparable to those of the nullizygous patients.
The Disease Severity of Specific ABCA4 Alleles IOVS j November 2016 j Vol. 57 j No. 14 j 5966
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935850/ on 12/05/2016
central atrophic lesion, surrounded by widespread flecks
(other than patients harboring intermediate p.R212C and
p.P1380L), often associated with a normal ERG (Fig. 5, second
column), while at the later stages the central atrophy was
larger and surrounded with widespread RPE mottling, and
usually associated with ERG group 2 or 3 (Fig. 5, third column).
There were three patients with foveal sparing, harboring
p.R24H, p.G863A, and p.L2027F (ages 34, 54, and 22 years,
respectively), all with normal ERGs. For the mutations
p.R212C, p.R1108C, and p.P1380L (classified as inter-
mediate), the age-matched homozygous patients all showed
notably greater RPE preservation outside the vascular arcades
(Fig. 4C). Null-like mutations were associated with foveal
atrophy in all cases and widespread FAF abnormalities,
qualitatively similar to the age-matched nullizygous phenotypes
(Fig. 5). Flecks were present only in the youngest patients,
while large areas of central atrophy and widespread mottling
were observed at older ages. Homozygous patients (available
for p.E1022K, p.E1087K, p.C1490Y, and p.T1526M) exhibited
similarly severe phenotypes (Fig. 4D). Figure 6 shows
representative OCT scans through the flecks associated with
intermediate and null mutations. The flecks in all cases
examined were located at the RPE level, but there was better
preservation of photoreceptor layers surrounding the flecks in
patients harboring intermediate mutations (Fig. 6B–D). The
association between FAF abnormalities and abnormal ERG was
strongly dependent on the genotype. Among patients with
widespread FAF irregularities, an abnormal ERG was observed
in 0%, 66%, and 100% cases for mild, intermediate, and null-like
mutations, respectively (significant for all intergroup compar-
isons, Fisher’s exact test, P < 0.005).
FIGURE 3. Box plot chart showing the distribution of LA 3.0 30-Hz
peak times for each of the studied mutations. Nullizygous and control
data are shown for reference. Mutations are arranged in the same order
as in Figure 1 (according to increasing age at disease onset, with
exception of p.G1961E). Number of patients with available data and
their median age are shown for each of the mutations.
FIGURE 4. Comparison of ERG and FAF of patients hemizygous or homozygous for the same mutation. Mutations p.R212C, p.P1380L, and p.R1108C
(A, C) were associated with a notably milder phenotype in homozygous states. Mutations p.E1022K, p.E1087K, p.T1526M, and p.C1490Y (B, D)
displayed similarly severe phenotypes in hemizygous and in homozygous states. H, homozygous.
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FIGURE 5. Representative fundus autofluorescence images of patients hemizygous for 15 different ABCA4 mutations. Mutations of different ERG
severity (mild, intermediate, and null-like) are shown in separate columns. Representative OCT scans are shown for p.G1961E and p.R2030Q to
note the qualitatively different macular phenotypes (all had a normal ERG). A FAF image of a patient with a normal ERG (ERG group 1) and an
abnormal ERG (ERG group 2 or 3) is shown for each intermediate mutation. An age-matched nullizygous patient is shown next to each nullizygous
patient (all had an abnormal ERG).
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DISCUSSION
Phenotypic Characteristics of Distinct ABCA4
Mutations
This study proposes a categorization of 15 distinct ABCA4
mutations into different severity classes based on the
departures of their hemizygous phenotypes (when in trans
with null) from the nullizygous phenotype. A summary of
clinical findings and topographical location of the studied
mutations are presented in Figure 7.
Mild Mutations (p.G1961E, p.R2030Q)
A mild phenotype associated with p.G1961E (normal ERGs,
absence of dark choroid, and low quantitative FAF) has been
reported previously,26,27 but mostly in compound heterozy-
gotes, carrying an additional missense mutation with an
unknown effect. An important finding in the current study is
that p.G1961E spares the peripheral retina when in a
hemizygous state. Interestingly, the macular FAF pattern was
different in the other mild mutation, p.R2030Q, causing a
foveal sparing phenotype and extensive FAF irregularities. This
corroborates reports on compound heterozygous patients, in
which p.R2030Q was the most common mutation involved in
foveal sparing,28 and p.G1961E in the optical gap phenotype
(i.e., isolated loss of photoreceptors in the fovea).29 It will be
important to use quantitative assessment of the FAF and OCT
images to strengthen and expand these observations in the
future. ABCA4-retinopathy is thought to be caused by at least
two contributing pathogenic mechanisms, one being RPE
damage triggered by phagocytosis of bisretinoid-laden outer
segments, and the other being direct cone toxicity12,30–32; and
it is tempting to speculate that the phenotypic differences
between p.G1961E and p.R2030Q reflect the predilection for
foveal cone damage for p.G1961E mutants and toward RPE
damage for p.R2030Q mutants.
Intermediate Mutations (p.R24H, p.G863A,
p.R1108c, p.P1380L, p.L2027F, c.5714þ5G>A)
Intermediate mutations must produce a sufficient amount of
functional ABCA4 protein to differentiate them from null;
however, there is deterioration of peripheral retinal function
with time. The FAF and OCT characteristics, that is, the
presence of widespread flecks in patients with normal ERG
and preserved photoreceptors surrounding the flecks on the
OCT, suggest that the presence of ABCA4 function not only
delays but may also modify the underlying pathophysiology of
retinal degeneration, potentially causing prevalent RPE toxicity
rather than direct photoreceptor toxicity. A quantitative
analysis of FAF and OCT images is needed to explore this
further. The p.G863A mutation is one of the most frequent
ABCA4 variants and was classified as mild in a previous study,13
although only patients with a normal scotopic ERG were
included, possibly skewing the genotype–phenotype correla-
tion. The present study suggests that when in trans with a null,
that mutation carries a considerable risk of retina-wide
degeneration after the fourth decade, although it may be
difficult to relay this information into clinical practice. There
was a degree of intra- and interallelic phenotypic variability
within the intermediate group. For example, the mutation
p.R24H may be associated with the highest ABCA4 function
within the group, as the patients had the latest median age at
the onset of visual symptoms, and foveal sparing was present
in the youngest patient. Conversely, p.R212C, p.R1108C, and
p.P1380L mutations may be associated with the lowest degree
FIGURE 6. FAF and OCT characteristics of flecks (arrows) associated with null/null-like and intermediate alleles. Patient hemizygous for p.E1087K
(null-like) mutation had qualitatively similar flecks to the nullizygous patients (first column), whereas the flecks of patients hemizygous for
intermediateþmutations were relatively larger and better delineated (second column). On the OCT scans (third column, location noted with green
lines), the flecks of nullizygous and intermediateþ patients correlated with RPE thickening with no obvious qualitative differences in terms of their
localization or shape (OCT of patients 31599 and 30989 were not available). However, the hyperreflective lines, representing photoreceptors (ISe
and ELM), appeared to be more preserved in patients harboring intermediateþmutations.
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of ABCA4 function. They were the only three mutations from
the intermediate group for which the median age of onset and
the ERG amplitudes in the late stages did not differ significantly
from the nullizygous group. Importantly, all three mutations
displayed a milder phenotype in a homozygous state,
suggesting a presence of some ABCA4 protein function.
Null-like Mutations (p.L541Pþp.A1038V, p.E1022K,
p.C1490Y, p.E1087K, p.T1526M, p.C2150Y)
The ages of onset, ERG amplitudes, and FAF abnormalities
associated with null-like mutations were mostly comparable to
those of the nullizygous patients. Ten of the studied mutations
were previously included in one or both of the two larger
genotype–phenotype studies to date14,15 (Table 2), but those
studies included compound heterozygotes and used subjective
parameters of visual function such as visual field and visual
acuity. Although direct comparison is difficult, there is general
agreement regarding the severe phenotype associated with
p.C2150Y and p.L541Pþp.A1038V, and comparatively milder
phenotype associated with p.G863A, p.P1380L, p.L2027F,
p.R2030Q, and p.G1961E. There was some discrepancy re-
garding c.5714þ5G>A, p.R1108C, and p.T1526M, which could
reflect the phenotypic variability within a specific genotype
and/or the fact that most patients in those studies harbored a
second variant of unknown severity. It has been suggested that
some ABCA4 mutations, including p.L541Pþp.A1038V (com-
plex allele) and p.C2150Y, produce a more severe phenotype
than the nullizygous genotype.14 None of the mutations in the
present study was associated with a more severe phenotype
than seen in nullizygous patients, including p.C2150Y, repre-
sented by a considerable number of patients. There was,
however, only one p.L541Pþp.A1038V patient, and more data
are needed to make a definitive conclusion regarding this allele.
A limitation of the study is that analysis of the clinical impact of
various hemizygous phenotypes cannot easily be extrapolated
FIGURE 7. The DA 10.0 a-wave amplitudes (A) and the LA 3.0 30-Hz amplitudes (B) of 82 patients hemizygous for 15 different mutations, and 20
nullizygous patients, plotted by age. The severity of mutations based on the analysis of the DA 10.0 a-wave amplitudes is marked with different
markers. The LA 30.0 30-Hz amplitudes were mostly consistent with the categorization. (C) Schematic representation of the median age of onset and
FAF progression for different classes of mutations. Mutations p.R2030Q and p.G1961E, although both mild according to the ERG, displayed
distinctly different FAF patterns. (D) Topographic model of ABCA4 protein showing the approximate location of the studied mutations. *For the
complex allele p.L541Pþp.A1038V, only the p.L541P is shown as red because it is considered the more pathogenic of the two based on previous
studies.10,11 Note the scale differences between charts A and B.
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to the more common situation in which the other mutation has
some activity. Although the homozygous patients for inter-
mediate alleles provide some evidence that two non-null
alleles could act in an additive manner, further studies are
needed to address this question.
Correlations With Prior Observations of Specific
Mutations
Review of in vitro observations, reported for p.G1961E,
p.G863A, p.R1108C, p.P1380L, p.L2027F, p.L541P, p.A1038V,
p.C1490Y, p.E1087K, and p.T1526M variants,5–8,33 revealed
several consistencies with the findings of the present study.
Most mutations were studied using human embryonic kidney
cell (HEK 293) cultures, allowing the assessment of the protein
yield (although retained in the endoplasmic reticulum) and its
affinity for adenosine triphosphatase (ATPase).6 A subset of
variants was additionally reconstituted into membranes and
tested for basal and retinal-stimulated ATPase activities.5,8,33
Mild Mutations
The p.G1961E ABCA4 mutant in vitro exhibited an unusual
ATPase activity profile in which the ATPase rate decreased with
increasing concentrations of transretinal, the opposite to wild-
type behavior, while its basal rate of ATPase activity was
otherwise comparable to wild-type constructs.6 The charac-
teristic phenotype of p.G1961E patients, in which disease
predominantly affects the fovea with little subsequent pathol-
ogy elsewhere, might suggest that the need to respond to
increasing transretinal concentration, over and above normal
basal activity, might be a specific requirement of foveal cone
photoreceptors.
Intermediate Mutations
The intermediate mutations p.G863A, p.R1108C, p.P1380L,
and p.L2027F shared similar in vitro characteristics, showing a
reduction in protein yields.6 The splicing mutation
c.5714þ5G>A has also been shown to result in a decreased
amount of (an otherwise normally spliced) product.20 Func-
tional experiments performed on p.G863A (for both the
missense change and the deletion of glycine) revealed a
reduction of basal ATPase activity but a preserved increase
with increasing concentrations of transretinal, resembling the
wild-type profile and opposite to that seen in p.G1961E,
suggesting a biochemical correlate with the distinct clinical
presentations.6 Reduced protein yield of misfolded mutant
peptides is due in part to their degradation by well-studied
cellular quality control mechanisms.34 An analogous phenom-
enon occurs in cystic fibrosis in which mutations of the gene
CTFR cause perturbation of a related ABC transporter
protein.35 Clinical trials are in progress to assess the efficacy
of a drug, VX-809, designed to reduced misfolding of specific
mutants.36 In vitro experiments have shown promising results
(i.e., increased protein yields) for the same approach applied to
ABCA4 mutations p.R1108C and p.R1129C.34 Other mutations
from the intermediate group may also be candidates for testing
the effect of such drugs.
Null-Like Mutations
The null-like mutations p.L541Pþp.A1038V, p.C1490Y,
p.E1087K, and p.T1526M shared similar in vitro characteristics
in terms of producing near-normal protein yields6,10 with
varying degrees of ATPase dysfunction, in some cases similar to
the in vitro profile of p.G1961E, which is surprising
considering that they produced a severe, null-like phenotype.
An important limitation of the studies using HEK 293 cells is
the inability to demonstrate defects of protein localization that
might be specific to the photoreceptor cells. Two of the
mutations from this subgroup (p.C1490Y and p.L541P, but not
p.A1038V) caused an almost complete mislocalization of the
ABCA4 protein to the photoreceptor inner segments of
transgenic frogs.11 Although this was not duplicated in the
p.L541Pþp.A1038V transgenic mouse, in which the mutant
protein seemed to be degraded,10 a similar mechanism could
be involved in pathogenesis in humans for those and other
mutations from this severe subgroup.
An obvious limitation of this study is the small number of
patients with some of the mutations, which was to some
extent ameliorated by recruiting homozygous patients for
those mutations. A further limitation was the difference in age
of patients at the time of ERG recordings. This was to a large
extent overcome by using the plots of ERG amplitudes against
age and utilizing the amplitude decline of the nullizygous
group as a baseline. Further longitudinal studies are neverthe-
less crucial to confirm these cross-sectional data. There was
also variation in the phenotype seen within each of the studied
genotypes, probably due to environmental or genetic modifier
influencing the phenotype, and a certain extent of overlap
between mutations of different classes of severity.
In conclusion, this study examines the effects of 15 ABCA4
mutations, each occurring in trans with a null, on age of onset
and on functional and structural retinal phenotypes. Quantified
ERG parameters of rod and cone system function are compared
with those of nullizygous ABCA4 cases across a wide range of
ages, identifying those likely to have residual function and
enabling mutations to be graded into different severity classes.
Additionally, the FAF patterns associated with those mutations
are described, including the distinct p.G1961E phenotype, and
the results interpreted in the context of in vitro studies to
generate hypotheses of the disease mechanisms. The data
inform our understanding of the effect of the genotype on the
clinical presentation of ABCA4-retinopathy and may be helpful
in the counseling and management of affected patients and
TABLE 2. Classification of ABCA4 Mutation on the Basis of ERGs
Severity Class/Mutation
Mild
p.G1961E14,15
p.R2030Q14
Intermediateþ
p.R24H
p.G863A13,15
c.5714þ5G>A14,15
p.L2027F14,15
Intermediate
p.R212C
p.R1108C15
p.P1380L14,15
Null-like
p.L541PþA1038V14,15
p.E1022K
p.C1490Y
p.E1087K
p.T1526M14
p.C2150Y14
Mutations included in previous genotype–phenotype studies are
noted with references.
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families, as well as in the optimum design and accurate
interpretation of future interventional trials.
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